May 1, 2025 10:09 AM EDTUpdated 10:32 AM
Deals

Af­ter hunt for al­ter­na­tives, Kro­nos Bio se­lects Tang Cap­i­tal's Con­cen­tra for a deal

Kyle LaHucik

Biotech Correspondent

Kro­nos Bio, the drug de­vel­op­er long led by Gilead vet­er­an Nor­bert Bischof­berg­er, is call­ing it quits.

The biotech said Thurs­day it’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The ‘MA­HA re­port’: Four key take­aways on vac­cines, med­i­cine and the phar­ma in­dus­try

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

FDA chief to sen­a­tors: 3,000+ staff de­par­tures won't de­lay user fee tar­gets

House pass­es Trump tax bill with PBM and or­phan drug re­forms in­clud­ed

Post-Hoc: AI bio needs to heed the over­hyped his­to­ry of CRISPR

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times